Video Game Hero Crash Bandicoot Urges Kids to Join the Fight Against Leukemia

08-08-2007

Crash is the New National Champion of The Leukemia & Lymphoma Society's School & Youth Programs

The Leukemia & Lymphoma Society and Vivendi Games today announced that Crash Bandicoot, the valiant, action hero of the highly popular video game series, is the new national champion for the Society's School & Youth programs.

The partnership comes as Sierra Entertainment, a division of Vivendi Games prepares for the launch of the latest incarnation of the top-selling Crash Bandicoot game franchise, "Crash of the Titans", available this October on the Xbox(TM) 360, PlayStation(R)2, Wii(TM), NintendoDS(TM), PSP(R), Game Boy(R) Advance and mobile phone platforms.

Throughout his video game adventures, Crash must battle the evil Dr. Neo Cortex and his no good ways. In joining forces with the Society, Crash now helps in the fight against leukemia, lymphoma and myeloma. Crash, the fun-loving, adventure seeking marsupial is always ready for a good fight and is a natural fit for the School & Youth programs, which are geared towards teaching kids about community service and helping kids with leukemia and other blood cancers. In the 2006-2007 school year, more than 21,000 schools participated in the program, raising more than $18 million for blood cancer research and patient services.

The Society and Vivendi Games anticipate that Crash's involvement will help attract more students to the Society's various youth programs due to his popularity with kids of all ages. More than 35 million Crash Bandicoot games have been sold worldwide since 1996, making Crash one of the most recognizable gaming and entertainment characters in the world.

"We are extremely honored to be partnering with the Society and in joining the battle against Leukemia, Lymphoma and Myeloma," said Mark Halacy, executive vice president of Human Resources for Vivendi Games. "Crash is a bandicoot with a big heart; he's brave, he's loyal and he's always ready for a good fight and a great cause. We feel this is a winning combination for a tremendous cause."

Crash Bandicoot will appear on the School & Youth recruitment posters and other printed materials as well as on the School & Youth Web site, newsletters, apparel and other items. Free downloads of Crash wallpaper and icons are available at http://www.schoolandyouth.org/.

"The Society is extremely excited about introducing Crash Bandicoot as the new national champion of School & Youth programs," said Nancy Klein, the Society's Senior Vice President of Marketing and Communications. "Crash is a fun, energetic character with tremendous appeal among kids and will help attract even wider interest in this life-saving campaign which has raised more than $100 million since its inception."

About School & Youth

School & Youth programs, which include "Pennies for Patients" and "HOP for Leukemia & Lymphoma," are value-building school-based programs in which students collect money, beginning with their own spare change to help the Society fund blood cancer research and patient services. These programs help students learn the value of achieving goals that benefit others and let them experience empathy and compassion.

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R), headquartered in White Plains, NY, with 68 chapters in the United States and Canada, is the world's largest voluntary health organization dedicated to funding blood cancer research and providing education and patient services. The Society's mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. Since its founding in 1949, the Society has invested more than $550 million in research specifically targeting leukemia, lymphoma and myeloma. Last year alone, the Society made 4.2 million contacts with patients, caregivers and healthcare professionals. For more information about blood cancer, visit http://www.lls.org/ or call the Society's Information Resource Center (IRC), a call center staffed by master's level social workers, nurses and health educators who provide information, support and resources to patients and their families and caregivers. IRC information specialists are available at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

About Vivendi Games

Vivendi Games (http://www.vivendigames.com/) is a global developer, publisher and distributor of multi-platform interactive entertainment with 16 offices around the world conducting business in 75 countries. Headquartered in Los Angeles, California, Vivendi Games and its four divisions - Blizzard Entertainment, Sierra Entertainment, Sierra Online and Vivendi Games Mobile - span the key areas of the industry. The company is the leader in the subscription-based massively multi-player online role-playing games (MMORPG) category with Blizzard Entertainment's blockbuster hit World of Warcraft(R) and has a significant presence in the console, handheld, PC, casual online and mobile gaming segments.

Contact: Andrea Greif
914.821.8958
andrea.greif@lls.org

Michele Guthrie
Vivendi Games
310.431.4560
Michele.guthrie@vgames.com

Website: http://www.schoolandyouth.org/
Website: http://www.lls.org/
Website: http://www.vivendigames.com/



Related Resources: The Leukemia and Lymphoma Society
 
RECENT NEWS
 
Acute Lymphocytic Leukemia (ALL)
Targeting Leukemia Cell's Gene 'addiction' Presents New Strategy For Treatment
Risk of leukemia with multiple sclerosis drug higher than thought
Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Hana Biosciences Announces New Positive Interim Efficacy Results in Pivotal rALLy Clinical Trial of Marqibo in Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia (AML)
Fewer platelets could be used for some cancer and bone-marrow transplantation patients
Cyclacel reports survival data from phase 2 sapacitabine study in elderly patients with acute myeloid leukemia
Risk of leukemia with multiple sclerosis drug higher than thought
A miR boost enables acute leukemia cells to mature
CSHL team develops mouse models of leukemia that predict response to chemotherapy
Amyloidosis
High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis
STEM CELL TRANSPLANTATION PROCEDURE RESULTS IN LONG-TERM SURVIVAL FOR AMYLOIDOSIS PATIENTS
Neurochem receives approvable letter for eprodisate (KIACTA) for treatment of AA amyloidosis
Neurochem, Inc. (NRMX) Receives Approvable Letter for Eprodisate (KIACTA(TM)) for Treatment of AA Amyloidosis; FDA Asks for More Data
Aplastic Anemia
Blood Stem Cells Originate in the Placenta
Stem Cells from a Person's Own Umbilical Cord Effective Treatment For Life-Threatening Blood Disease, Study Data Show
Alexion's Soliris Granted Marketing Approval in Europe for Treatment of All Patients With PNH
Soliris(TM) Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
Decision Fails Patients with Transfusion-Dependent Anemia
Chronic Lymphocytic Leukemia (CLL)
ASCO Presentation Highlights Memgen's ISF35 Anti-Cancer Activity in Chronic Lymphocytic Leukemia
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Azerra MAA Accepted by EMEA for CLL
Roche's MabThera approved in Europe for CLL
Chronic Myeloid Leukemia (CML)
Targeting Leukemia Cell's Gene 'addiction' Presents New Strategy For Treatment
Deciphera Pharmaceuticals Announces Initation of DCC-2036 Phase 1 Clinical Trial in Refractory CML and ALL
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Scientists Gain Insight Into Blood Cancer's Progression
Some blood-system stem cells reproduce more slowly than expected
Hodgkin Lymphoma
Bone marrow stem cell co-transplantation prevents embryonic stem cell transplant-associated tumors
Seattle Genetics Receives FDA Fast Track Designation for SGN-35 for the Treatment of Hodgkin Lymphoma
Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
Hodgkin lymphoma -- new characteristics discovered
Multiple Myeloma
New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
Green Tea May Negate the Benefits of Velcade
Keryx Biopharmaceuticals (KERX) Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
Velcade® plus Perifosine Shows Promise in Relapsed or Refractory Multiple Myeloma
Mozobil™ Approved for Stem Cell Mobilization in NHL and MM Patients
Myelodysplastic Syndrome (MDS)
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Seattle Genetics Completes Enrollment in Lintuzumab Phase IIb Clinical Trial for Patients with Acute Myeloid Leukemia
New Risk Model for MDS Applies to All Stages of Disease
Seattle Genetics Announces Interim Safety Analysis Supports Continuation of Lintuzumab Phase IIb Clinical Trial
CHMP Awards Positive Opinion for Myelodysplastic Syndrome Drug
Non-Hodgkin Lymphoma (NHL)
Genentech and Biogen Idec Submit Applications to the FDA for Rituxan for Most Common Type of Adult Leukemia
Allos Therapeutics Submits New Drug Application for Pralatrexate for Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Spectrum Pharmaceuticals, Inc. Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Study shows that maintenance rituximab is useful for advanced indolent lymphoma
Advances in the Treatment of Aggressive Non-Hodgkin’s Lymphoma
Testicular Cancer
New Genes Linked to Testicular Cancer
Second gene linked to familial testicular cancer
Male Infertility Linked to Testicular Cancer
Single Dose of Carboplatin as Effective as Radiation Therapy for Testicular Cancer
Single Dose of Chemotherapy as Effective as Weeks of Radiation Therapy for Testicular Cancer